BACKGROUND: Diagnosing invasive aspergillosis is difficult but might be improved by detection of circulating galactomannan. Although galactomannan antigenemia has been well studied in the detection of invasive aspergillosis in adult patients, little is known about the expression of circulating galactomannan in immunocompromised children with invasive aspergillosis. METHODS: We studied the expression of galactomannan antigen by enzyme immunoassay (EIA) in 990 serum samples from 56 pediatric oncology patients (ages 3 months to 18 years) of whom 17 had proven or probable invasive aspergillosis defined by the European Organization for Research and Treatment of Cancer-Mycoses Study Group criteria. Any sample with a galactomannan EIA Galactomannan index value of > or = 0.5 was considered positive. RESULTS: At least 1 serum sample was positive for 11 of 17 pediatric oncology patients (65.7% sensitivity, 95% confidence interval: 38.3-85.7) with invasive aspergillosis. Galactomannan EIA was positive in 99 of 304 samples from patients with proven or probable invasive aspergillosis, and 7 of 686 (1.0%) samples from 39 control subjects resulted in a positive galactomannan EIA result. At least 1 sample tested positive in 5 of the 39 controls (12.8%, 95% confidence interval: 4.3-27.4). No significant association between accuracy and patient age was observed. Among the 7 evaluable galactomannan-positive patients with IA, the galactomannan EIA produced a positive result before clinical or radiographic evidence of infection in 6 cases, with a lead-time to diagnosis ranging from 1 day to 34 days (median: 10 days). In the remaining case, a positive galactomannan was observed on the same day as diagnosis by non-EIA methods. CONCLUSIONS: The presence of circulating galactomannan is predictive of invasive aspergillosis in most pediatric oncology patients. Galactomannan antigenemia may precede clinical, microbiologic, or radiographic evidence of invasive aspergillosis.
BACKGROUND: Diagnosing invasive aspergillosis is difficult but might be improved by detection of circulating galactomannan. Although galactomannan antigenemia has been well studied in the detection of invasive aspergillosis in adult patients, little is known about the expression of circulating galactomannan in immunocompromised children with invasive aspergillosis. METHODS: We studied the expression of galactomannan antigen by enzyme immunoassay (EIA) in 990 serum samples from 56 pediatric oncology patients (ages 3 months to 18 years) of whom 17 had proven or probable invasive aspergillosis defined by the European Organization for Research and Treatment of Cancer-Mycoses Study Group criteria. Any sample with a galactomannan EIA Galactomannan index value of > or = 0.5 was considered positive. RESULTS: At least 1 serum sample was positive for 11 of 17 pediatric oncology patients (65.7% sensitivity, 95% confidence interval: 38.3-85.7) with invasive aspergillosis. Galactomannan EIA was positive in 99 of 304 samples from patients with proven or probable invasive aspergillosis, and 7 of 686 (1.0%) samples from 39 control subjects resulted in a positive galactomannan EIA result. At least 1 sample tested positive in 5 of the 39 controls (12.8%, 95% confidence interval: 4.3-27.4). No significant association between accuracy and patient age was observed. Among the 7 evaluable galactomannan-positive patients with IA, the galactomannan EIA produced a positive result before clinical or radiographic evidence of infection in 6 cases, with a lead-time to diagnosis ranging from 1 day to 34 days (median: 10 days). In the remaining case, a positive galactomannan was observed on the same day as diagnosis by non-EIA methods. CONCLUSIONS: The presence of circulating galactomannan is predictive of invasive aspergillosis in most pediatric oncology patients. Galactomannan antigenemia may precede clinical, microbiologic, or radiographic evidence of invasive aspergillosis.
Authors: Daniel Kelly Benjamin; William C Miller; Sherry Bayliff; Lisa Martel; Kenneth A Alexander; Paul Langlie Martin Journal: Pediatr Infect Dis J Date: 2002-03 Impact factor: 2.129
Authors: S Ascioglu; J H Rex; B de Pauw; J E Bennett; J Bille; F Crokaert; D W Denning; J P Donnelly; J E Edwards; Z Erjavec; D Fiere; O Lortholary; J Maertens; J F Meis; T F Patterson; J Ritter; D Selleslag; P M Shah; D A Stevens; T J Walsh Journal: Clin Infect Dis Date: 2001-11-26 Impact factor: 9.079
Authors: T J Walsh; N L Seibel; C Arndt; R E Harris; M J Dinubile; A Reboli; J Hiemenz; S J Chanock Journal: Pediatr Infect Dis J Date: 1999-08 Impact factor: 2.129
Authors: D Stynen; J Sarfati; A Goris; M C Prévost; M Lesourd; H Kamphuis; V Darras; J P Latgé Journal: Infect Immun Date: 1992-06 Impact factor: 3.441
Authors: Anna R Huppler; Brian T Fisher; Thomas Lehrnbecher; Thomas J Walsh; William J Steinbach Journal: J Pediatric Infect Dis Soc Date: 2017-09-01 Impact factor: 3.164
Authors: Thomas J Walsh; Mark C Wissel; Kevin J Grantham; Ruta Petraitiene; Vidmantas Petraitis; Miki Kasai; Andrea Francesconi; Margaret P Cotton; Johanna E Hughes; Lora Greene; John D Bacher; Pradip Manna; Martin Salomoni; Steven B Kleiboeker; Sushruth K Reddy Journal: J Clin Microbiol Date: 2011-10-05 Impact factor: 5.948
Authors: Ruta Petraitiene; Vidmantas Petraitis; John R Witt; Michelle M Durkin; John D Bacher; L Joseph Wheat; Thomas J Walsh Journal: J Clin Microbiol Date: 2011-10-05 Impact factor: 5.948
Authors: Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett Journal: Clin Infect Dis Date: 2016-06-29 Impact factor: 9.079
Authors: Brian T Fisher; Theoklis E Zaoutis; Julie R Park; Marie Bleakley; Janet A Englund; Christine Kane; Robert J Arceci; Eva Guinan; Franklin O Smith; Xianqun Luan; Kieren A Marr Journal: J Pediatric Infect Dis Soc Date: 2012-05-03 Impact factor: 3.164
Authors: Mariska M G Leeflang; Yvette J Debets-Ossenkopp; Junfeng Wang; Caroline E Visser; Rob J P M Scholten; Lotty Hooft; Henk A Bijlmer; Johannes B Reitsma; Mingming Zhang; Patrick M M Bossuyt; Christina M Vandenbroucke-Grauls Journal: Cochrane Database Syst Rev Date: 2015-12-30
Authors: Seung Beom Han; Seong Koo Kim; E Young Bae; Jae Wook Lee; Jong-Seo Yoon; Nack-Gyun Chung; Bin Cho; Dae Chul Jeong; Jin Han Kang; Hack-Ki Kim; Dong-Gun Lee; Hyun Sil Lee; Soo Ah Im Journal: J Korean Med Sci Date: 2015-07-15 Impact factor: 2.153